Lo-zumandimine Kit
Product Images NDC 59651-029

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Lo-zumandimine (NDC 59651-029). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Vte Risk With Yasmin Relative To Lng-containing Cocs (adjusted Risk#) (Drospirenone Fig1)

A logarithmic scale forest plot displaying adjusted venous thromboembolism (VTE) risk ratios for Yasmin relative to LNG-containing combined oral contraceptives (COCs). It presents hazard ratios, rate ratios, and odds ratios from multiple studies including prospective and retrospective cohorts, case-control, and non-fatal idiopathic cases. The plot shows risk ratio values with 95% confidence intervals for each study listed.*

FDA Label Image

Figure 2: Likelihood Of Developing A Vte (Drospirenone Fig2)

Bar chart titled 'Likelihood of Developing a VTE' illustrating the estimated number of women with a blood clot per 10,000 women years across four groups: Non-Pregnant Non-COC users (1 to 5 cases), COC users (3 to 9 cases), Pregnancy (5 to 20 cases), and Postpartum (12 weeks only) (40 to 65 cases). The x-axis represents the number of cases, with values from 0 to 70.*

FDA Label Image

Figure 3 (Drospirenone Fig3)

A forest plot titled 'Ever COC vs. Never COC Use' and 'Current COC use vs. Never-Use' showing effect estimates with confidence intervals from several studies, including NICHD Women's Care Study and Nurses' Health Study II. The horizontal axis measures effect estimates from -1.50 to 2.00, and points with error bars represent odds ratios (OR), relative risks (RR), and hazard ratios (HR) with confidence intervals for each study.*

FDA Label Image

Figure-2 (Drospirenone Fig4)

A vertical chart illustrating pregnancy rates per 100 women in one year, arranged from fewer to more pregnancies. It categorizes birth control methods by effectiveness: implants, injections, intrauterine devices, and sterilization are shown as most effective (fewer than 1 pregnancy); birth control pills, skin patch, and vaginal ring with hormones are next; condoms and diaphragm follow; no sex during fertile days, spermicide, and withdrawal are less effective; and no birth control is the least effective with 85 or more pregnancies per 100 women.*

FDA Label Image

Package Label-principal Display Panel (3 mg/0.02 mg Pouch Label)

An illustrated calendar-style chart for Lo-Zumandimine (Drospirenone and Ethinyl Estradiol Tablets, USP) 3 mg/0.02 mg, designed to guide daily oral tablet intake over four weeks. The chart displays days of the week—Sunday through Saturday—in horizontal rows labeled Week 1 through Week 4, with circular placeholders representing each tablet dose to be taken.*

FDA Label Image

Package Label-principal Display Panel (3 mg/0.02 mg Pouch Carton)

A horizontal bar chart comparing the number of women with a blood clot per 10,000 woman-years (WY) across four groups: Non-Pregnant Non-COC users, COC-users, Pregnant women, and Postpartum women (12 weeks only). The chart displays the range of blood clot cases for each group, with Postpartum women having the highest range, followed by Pregnant women, COC-users, and Non-Pregnant Non-COC users. A footnote explains pregnancy data assumptions.*

FDA Label Image

Drospirenone Fig7

Label for Lo-Zumandimine(TM) tablets containing Drospirenone and Ethinyl Estradiol USP, 3 mg/0.02 mg per tablet. The label indicates one blister pack of 28 tablets per pouch, with prescription use only. The product is distributed by Aurobindo Pharma USA and made in India, featuring a multi-color design with green and yellow gradient background and the Aurobindo logo.*

FDA Label Image

Drospirenone Fig8

Packaging label for Lo-Zumandimine tablets USP, 3 mg/0.02 mg, a kit containing 3 individual pouches each with a blister pack of 28 tablets. Distributed by Aurobindo Pharma USA, Inc., the label includes dosage form and strength, manufacturer information, storage instructions, and a barcode. The design features a gradient background with blue and yellow-green waves and the Aurobindo logo.*

FDA Label Image

Chemical Structure (Drospirenone Str)

Chemical structure diagram showing the molecular formulas of the active ingredients Drospirenone and Ethinyl Estradiol in the medication Lo-Zumandimine.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.